Viral CTLs + Standard Care for Cytomegalovirus Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
Who Is on the Research Team?
Mitchell Cairo, MD
Principal Investigator
New York Medical College
Are You a Good Fit for This Trial?
This trial is for children and young adults (up to age 30) who have had a stem cell transplant and now have ADV or CMV infections that aren't improving with standard antiviral treatments, can't tolerate these medicines, or the virus is resistant. Participants need a matched family donor available for special immune cells.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Viral CTLs
Trial Overview
The study compares two groups: one gets standard antiviral medications plus special infection-fighting immune cells from a family donor (viral CTLs), while the other group receives only standard antiviral care. Patients are randomly assigned to each group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients will be randomized to receiving standard of care antiviral therapy plus family matched donor derived CTLs.
Patients will receive standard of care antiviral therapy for CMV or ADV at the discretion of the physician.
Find a Clinic Near You
Who Is Running the Clinical Trial?
New York Medical College
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.